B. BRAUN MIETHKE GMBH & Co. KG

What B. BRAUN MIETHKE GMBH & Co. KG does

B. Braun Miethke GmbH & Co. KG is a German medical device joint venture established in 2017 and headquartered in Potsdam, Brandenburg. It is co-owned by Aesculap AG, a wholly-owned subsidiary of B. Braun Melsungen AG (a major medical technology and pharmaceutical group), and Christoph Miethke, founder and CEO of Christoph Miethke GmbH & Co. KG. The two parent companies have maintained a collaboration in targeted drug delivery since 1999, and the joint venture extends that partnership into a dedicated product development entity. B. Braun Miethke Verwaltungs GmbH serves as the general partner of the Kommanditgesellschaft structure.

The company is developing a portfolio of implantable medical devices that deliver pharmaceutical compounds directly to the site of action within the body, in contrast to conventional oral systemic administration. This targeted approach is designed to increase drug efficacy while enabling significantly reduced dosages and fewer side effects. The initial therapeutic focus is chronic pain and severe spasticity, addressing conditions treated by neurologists, pain specialists, and related physicians, with end beneficiaries being patients requiring long-term pharmacologic management. The company is currently in the development stage and has not yet commercialized products.

The company operates with a small team (approximately 13 employees, including management, engineers, software developers, machinists, and student workers) under CEO Brandon Loudermilk, alongside co-founders Christoph Miethke and managing director Jochen Becker. Its go-to-market model is enterprise-oriented, leveraging the established sales networks, clinical relationships, manufacturing capabilities, and regulatory infrastructure of B. Braun and Aesculap rather than building independent distribution. Revenue is expected to derive from hardware sales of the implantable drug delivery products once commercialized, though no pricing, revenue figures, or product launch dates are publicly disclosed. The company currently markets itself primarily through its bilingual (German/English) corporate website and recruits via direct applications.

Name

B. BRAUN MIETHKE GMBH & Co. KG

Legal name

B. Braun Miethke GmbH & Co. KG

Website

https://bbraun-miethke.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

B. Braun Miethke GmbH & Co. KG is a Potsdam-based medical device joint venture developing implantable targeted drug delivery systems for chronic pain and severe spasticity, serving neurologists, pain specialists, and patients through the B. Braun and Aesculap distribution platform.

Ownership category

akta.pro rank

Product category

Implantable Drug Delivery Systems

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)

Keywords

• Targeted drug delivery
• Implantable medical devices
• Chronic pain therapy
• Spasticity treatment
• Neurosurgical implants

Headquarters

HQ city

Potsdam

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Others

Revenue model

1. Medical Device / Implant Sales: Revenue is derived from the sale of innovative implantable drug delivery products targeting healthcare professionals who treat patients with chronic pain and severe spasticity. The company is a joint venture structured to commercialize novel medical technologies developed in partnership with Aesculap and Christoph Miethke.

Go-to-market motion1 record

Marketing channels2 records

Core offering

B. Braun Miethke develops innovative implantable medical devices for targeted drug delivery, designed to administer pharmaceutical compounds directly to the site of action within the body. The implants increase drug efficacy and enable significantly reduced dosages compared to conventional oral administration, thereby minimizing undesirable systemic side effects. The products are intended for physicians and clinical use in treating patients with chronic pain and severe spasticity.

Product overview

B. Braun Miethke is developing a focused portfolio of innovative implants for targeted drug delivery. Their primary product category consists of implantable medical devices designed to deliver medications directly to the site of action within the body. This targeted approach increases drug efficacy and allows for significantly reduced dosages, minimizing adverse side effects for patients suffering from chronic pain and severe spasticity. The company is currently in the development stage, leveraging expertise and infrastructure from parent companies Aesculap AG and Christoph Miethke GmbH & Co. KG.

Differentiator

Problem solved

Functional benefit

Products and services

• Targeted Drug Delivery Implants Implantable medical devices designed to deliver pharmaceutical compounds directly to the site of action within the body, enabling higher drug efficacy at significantly reduced doses compared to conventional oral administration and minimizing undesirable systemic side effects. Intended for physicians treating patients with chronic pain and severe spasticity.

Quantifiable outcome

• Drug doses can be significantly reduced compared to conventional oral administration, resulting in fewer side effects

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Three partnerships are on record, tiered core.

• Aesculap AGcoreStrategic or Co-development PartnerAesculap AG is a subsidiary of B. Braun Melsungen AG and is one of the two parent companies of the B. Braun Miethke joint venture. The partnership leverages Aesculap's expertise in medical technology, manufacturing capabilities, and established market channels. B. Braun Miethke benefits from close cooperation and exchange with Aesculap for the development and commercialization of targeted drug delivery implants.
• Christoph Miethke GmbH & Co. KGcoreStrategic or Co-development PartnerChristoph Miethke GmbH & Co. KG, founded by Christoph Miethke in 1992 in Potsdam, is the second parent company of the joint venture. Christoph Miethke brings decades of specialized expertise in targeted drug delivery technology, multiple innovation awards, and a partnership history with B. Braun dating back to 1999. B. Braun Miethke leverages this specialized knowledge for the development of innovative drug delivery implants.
• B. Braun Melsungen AGcoreStrategic or Co-development PartnerB. Braun Melsungen AG is a major medical technology and pharmaceutical company based in Germany. Through its subsidiary Aesculap AG, it is the majority parent of the B. Braun Miethke joint venture. B. Braun provides substantial capital resources, market reach, regulatory expertise, and operational infrastructure to support the joint venture's R&D and commercialization activities in targeted drug delivery.

Scale indicators2 records

Recent moves6 records

Expansion highlights3 records

Direct peers

• Flowonix Medical: Flowonix manufactures the Prometra and Prometra II programmable intrathecal infusion pumps — a direct, narrowly focused competitor in targeted drug delivery for pain and spasticity.
• Medtronic: Medtronic's Neuromodulation and Pain Therapies businesses (SynchroMed intrathecal drug delivery pumps, Intellis neurostimulators) directly compete in implantable therapies for chronic pain and severe spasticity — the same indications B. Braun Miethke targets.
• Integra LifeSciences (Codman & Shurtleff): Integra Codman historically manufactured intrathecal drug delivery pumps and neurosurgical instruments for pain, hydrocephalus, and spasticity — directly overlapping with B. Braun Miethke's implantable device focus.
• Nevro Corp: Nevro specializes in 10 kHz HF10 high-frequency spinal cord stimulation for chronic pain, a closely competing implantable neuromodulation approach for the same patient populations B. Braun Miethke targets.

Emerging players

• Mainstay Medical: Mainstay Medical commercializes the ReActiv8 restorative neurostimulation system for chronic mechanical low back pain — an emerging implantable player in adjacent chronic-pain indications.
• Saluda Medical: Saluda is developing next-generation closed-loop spinal cord stimulation systems (Evoke) for chronic pain — an emerging implantable device competitor pursuing the same indications as B. Braun Miethke.
• Stimwave / Curonix: Curonix (formerly Stimwave) develops miniaturized, wireless injectable neurostimulators for chronic pain — emerging technology that intersects with B. Braun Miethke's targeted implant-based therapy category.

Broad incumbents

• Boston Scientific: Boston Scientific's Neuromodulation division (Precision Spectra, WaveWriter) provides implantable devices for chronic pain within a much wider medtech portfolio, overlapping with B. Braun Miethke's clinical focus area.
• Stryker (Neurotechnology & Spine): Stryker offers neurotechnology and spine devices used in the same surgical specialties that implant drug delivery pumps, including instruments and adjacent implantable therapies for chronic pain management.
• Abbott (Abbott Neuromodulation): Abbott offers the Proclaim XR and Eterna neurostimulation systems for chronic pain and movement disorders, overlapping with B. Braun Miethke's implantable therapy focus as part of a much broader device portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/b.-braun-miethke-gmbh-&-co.-kg

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about B. BRAUN MIETHKE GMBH & Co. KG